Orbital involvement of invasive fungal sinusitis (IFS) is an ominous prognostic marker that should prompt rapid intervention. Transcutaneous retrobulbar administration of amphotericin B (TRAMB) is an off-label adjunctive treatment that can increase drug penetrance into diseased orbital tissue. To date, there is a lack of consensus regarding the use of TRAMB for treatment of IFS with orbital involvement.
Objective
This systematic review aims to synthesize the indications, efficacy, and potential complications of TRAMB.
Methods
PubMed, EMBASE, and Web of Science databases were probed for systematic review. Article search was conducted through June 2023 using the keywords “invasive fungal sinusitis,” “invasive fungal rhinosinusitis,” “rhino-orbital mucormycosis,” “rhinosinusitis,” “orbital,” “retrobulbar,” and “amphotericin.”
Results
In suitable cases as determined by radiologic and clinical evaluation, TRAMB administration has the potential to improve orbital salvage rates and improve versus stabilize visual acuity. Treatment complications are more likely with deoxycholate than with liposomal amphotericin formulations. The existing literature describing use of TRAMB is limited due to its retrospective nature, but the increase in IFS cases since 2020 due to the COVID pandemic has broadened the literature.
Conclusions
TRAMB is an effective adjunctive treatment in IFS with mild-to-moderate orbital involvement when used in combination with standard of care debridement, systemic antifungal therapy, and immunosuppression reversal. Prospective longitudinal studies and multi-institutional randomized trials are necessary to determine the definitive utility of TRAMB.
Kalin-HajduEHirabayashiKEVagefiMRKerstenRC. Invasive fungal sinusitis: treatment of the orbit. Curr Opin Ophthalmol. 2017;28(5):522–533. doi:https://doi.org/10.1097/icu.0000000000000394
2.
TurnerJHSoudryENayakJVHwangPH. Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence. Laryngoscope. 2013;123(5):1112–1118. doi:https://doi.org/10.1002/lary.23912
3.
ParikhSLVenkatramanGDelGaudioJM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol. 2004;18(2):75–81.
4.
SaediBSadeghiMSeilaniP. Endoscopic management of rhinocerebral mucormycosis with topical and intravenous amphotericin B. J Laryngol Otol. 2011;125(8):807–810. doi:https://doi.org/10.1017/s0022215111001289
5.
HirabayashiKEKalin-HajduEBrodieFLKerstenRCRussellMSVagefiMR. Retrobulbar injection of amphotericin B for orbital mucormycosis. Ophthalmic Plast Reconstr Surg. 2017;33(4):e94–e97. doi:https://doi.org/10.1097/iop.0000000000000806
6.
DaveTVGopinathan NairAHegdeR, et al.Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: a multi-centric study. Ophthalmic Plast Reconstr Surg. 2021;37(5):488–495. doi:https://doi.org/10.1097/iop.0000000000002030
7.
IdowuOOSoderlundKALagunaB, et al.Magnetic resonance imaging prognostic findings for visual and mortality outcomes in acute invasive fungal rhinosinusitis. Ophthalmology. 2022;129(11):1313–1322. doi:https://doi.org/10.1016/j.ophtha.2022.06.020
8.
HirabayashiKEIdowuOOKalin-HajduE, et al.Invasive fungal sinusitis: risk factors for visual acuity outcomes and mortality. Ophthalmic Plast Reconstr Surg. 2019;35(6):535–542. doi:https://doi.org/10.1097/iop.0000000000001357
9.
NairAGDaveTV. Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review. Orbit. 2022;41(3):275–286. doi:https://doi.org/10.1080/01676830.2021.1990351
10.
TwuKHKuoYJHoCYKuanECWangWHLanMY. Invasive fungal rhinosinusitis with and without orbital complications: clinical and laboratory differences. J Fungi (Basel). 2021;7(7):573. doi:https://doi.org/10.3390/jof7070573
11.
Colon-AcevedoBKumarJRichardMJWoodwardJA. The role of adjunctive therapies in the management of invasive sino-orbital infection. Ophthalmic Plast Reconstr Surg. 2015;31(5):401–405. doi:https://doi.org/10.1097/iop.0000000000000488
12.
RolandLTHumphreysIMLeCH, et al.Diagnosis, prognosticators, and management of acute invasive fungal rhinosinusitis: multidisciplinary consensus statement and evidence-based review with recommendations. Int Forum Allergy Rhinol. 2023;13(9):1615–1714. doi:https://doi.org/10.1002/alr.23132
13.
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:https://doi.org/10.1371/journal.pmed.1000097
14.
CarbiaCLópez-CanedaECorralMCadaveiraF. A systematic review of neuropsychological studies involving young binge drinkers. Neurosci Biobehav Rev. 2018;90:332–349. doi:https://doi.org/10.1016/j.neubiorev.2018.04.013
15.
ShakrawalJSharmaVGoyalA, et al.Outcomes of transcutaneous retrobulbar amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19. Int Ophthalmol. 2023;43(6):1919–1926. doi:https://doi.org/10.1007/s10792-022-02591-0
16.
RizviSWAKhanSShahbazMGounderMSSaifMKhalidS. Long-term outcomes of transcutaneous retrobulbar amphotericin B in COVID-19-associated mucormycosis. Indian J Ophthalmol. 2023;71(2):452–456. doi:https://doi.org/10.4103/ijo.IJO_1382_22
17.
GandhiANarulaAChandraS, et al.Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study. Int Ophthalmol. 2023;43(5):1571–1580. doi:https://doi.org/10.1007/s10792-022-02556-3
18.
YadavHSenSNathT, et al.Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in northern India. Indian J Ophthalmol. 2022;70(6):2163–2168. doi:https://doi.org/10.4103/ijo.IJO_340_22
19.
KharePChaurasiaYBhatnagarS. Exploring the globe salvaging treatment options in patients of COVID-19-associated mucormycosis with orbital involvement. Indian J Ophthalmol. 2022;70(10):3638–3642. doi:https://doi.org/10.4103/ijo.IJO_938_22
20.
BayramNOzsaygılıCSavH, et al.Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol. 2021;65(4):515–525. doi:https://doi.org/10.1007/s10384-021-00845-5
21.
YadavRMadanSRohatgiJ, et al.Retrospective analysis of the role of retrobulbar amphotericin-B injection in the management of COVID-19 associated rhino-orbito-cerebral-mucormycosis. Pan Afr Med J. 2022;42:312. doi:https://doi.org/10.11604/pamj.2022.42.312.34757
22.
SinhaSKumarVBKumarA, et al.Outcomes of transcutaneous retrobulbar amphotericin B in rhino-orbital-cerebral mucormycosis among patients recovering from COVID-19: a preliminary experience. Cureus. 2022;14(8):e27817. doi:https://doi.org/10.7759/cureus.27817
23.
PatelMPanchalJDesaiCShahJPrajapatiBPatelS. Emergence of cerebral mucormycosis in the post-COVID period: a detailed analysis of risk factors, clinical progression, and management of this opportunistic fungal infection. Cureus. 2022;14(11):e31220. doi:https://doi.org/10.7759/cureus.31220
24.
AshrafDCIdowuOOHirabayashiKE, et al.Outcomes of a modified treatment ladder algorithm using retrobulbar amphotericin B for invasive fungal rhino-orbital sinusitis. Am J Ophthalmol. 2022;237:299–309. doi:https://doi.org/10.1016/j.ajo.2021.05.025
25.
DallalzadehLOEdiriwickremaLSFungSE, et al.Transcutaneous retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis: a multi-center retrospective comparative study. Orbit. 2023;43(1):1–8. doi:https://doi.org/10.1080/01676830.2023.2186435
26.
RamamurthyLBBhandariRKanakpurSThejaswiniP. Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: our experience. Indian J Ophthalmol. 2022;70(3):1019–1024. doi:https://doi.org/10.4103/ijo.IJO_2356_21
27.
PathakMSahuVAroraRD, et al.Retrobulbar amphotericin B injection in curbing the progression of COVID associated rhino-orbital cerebral mucormycosis: a retrospective case series. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 2):3352–3358. doi:https://doi.org/10.1007/s12070-022-03199-7
28.
ArreenichPSaonanonPAeumjaturapatSSnidvongsKChusakulSKanjanaumpornJ. Efficacy and safety of retrobulbar amphotericin B injection in invasive fungal rhinosinusitis with orbital invasion patients. Rhinology. 2021;59(4):387–392. doi:https://doi.org/10.4193/Rhin21.070
29.
NairAGAdulkarNGD'CunhaL, et al.Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. Orbit. 2021;40(6):499–504. doi:https://doi.org/10.1080/01676830.2021.1960382
30.
DallalzadehLOEdiriwickremaLSFungSE, et al.Transcutaneous retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis: a multi-center retrospective comparative study. Orbit. 2023;43(1):1–8. doi:https://doi.org/10.1080/01676830.2023.2186435
31.
HargroveRNWesleyREKlippensteinKAFlemingJCHaikBG. Indications for orbital exenteration in mucormycosis. Ophthalmic Plast Reconstr Surg. 2006;22(4):286–291. doi:https://doi.org/10.1097/01.iop.0000225418.50441.ee
32.
KashkouliMBAbdolalizadehPOghazianMHadiYKarimiNGhazizadehM. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis. Br J Ophthalmol. 2019;103(10):1460–1465. doi:https://doi.org/10.1136/bjophthalmol-2018-312688
33.
HonavarSG. Code Mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol. 2021;69(6):1361–1365. doi:https://doi.org/10.4103/ijo.IJO_1165_21
34.
HarmsenSMcLarenACPaukenCMcLemoreR. Amphotericin B is cytotoxic at locally delivered concentrations. Clin Orthop Relat Res. 2011;469(11):3016–3021. doi:https://doi.org/10.1007/s11999-011-1890-2
SharifiAAkbariZShafie'eiM, et al.Retrobulbar injection of amphotericin B in patients with COVID-19 associated orbital mucormycosis: a systematic review. Ophthalmic Plast Reconstr Surg. 2022;38(5):425–432. doi:https://doi.org/10.1097/iop.0000000000002256
38.
SafiMAngMJPatelPSilkissRZ. Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Am J Ophthalmol Case Rep. 2020;19:100771. doi:https://doi.org/10.1016/j.ajoc.2020.100771
39.
BrodieFLKalin-HajduEKuoDSHirabayashiKEVagefiRKerstenRC. Orbital compartment syndrome following retrobulbar injection of amphotericin B for invasive fungal disease. Am J Ophthalmol Case Rep. 2016;1:8–10. doi:https://doi.org/10.1016/j.ajoc.2016.01.003
40.
McCallumEKerenSLapiraMNorrisJH. Orbital compartment syndrome: an update with review of the literature. Clin Ophthalmol. 2019;13:2189–2194. doi:https://doi.org/10.2147/opth.S180058
